Evaluation of Safety and Efficacy of the 3F Applicator (A3F) for Treatment of Facial Wrinkles

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-03-31

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The 3F Applicator (A3F) is indicated for use in dermatological procedures requiring ablation and resurfacing of the skin, and for the treatment of facial wrinkles. This study was designed in order to evaluate the safety and efficacy of the A3F for treatment of facial wrinkles.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The need for cosmetic facial enhancement procedures with minimal down time and low risk has led to the development of methods for non-surgical skin rejuvenation. Various ablative lasers were developed, which remove the full skin surface in a controlled manner1,2. However, the prolonged recovery and the significant risks prompted the development of fractional lasers which ablate the skin in a fractional manner, leaving untreated areas to improve healing process3. In the past few years, fractional RF systems have been introduced that enable controlled skin resurfacing accompanied with dermal collagen remodeling4,5,6. The new 3F Applicator (A3F, trade name TriFractional) from Pollogen™ is designed to enable skin resurfacing and treatment of wrinkles using radiofrequency energy.

The 3F Applicator (A3F) is indicated for use in dermatological procedures requiring ablation and resurfacing of the skin, and for the treatment of facial wrinkles. This study was designed in order to evaluate the safety and efficacy of the A3F for treatment of facial wrinkles.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Facial Wrinkles

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Fractional, RF, Wrinkles Safety Efficacy treatment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A3F

A3F, Fractional RF treatment

Group Type EXPERIMENTAL

A3F

Intervention Type DEVICE

A3F fractional RF treatments for facial wrinkles

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

A3F

A3F fractional RF treatments for facial wrinkles

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject read, understood and signed the Consent Form
2. Healthy female/male aged 35 65 years,
3. Fitzpatrick wrinkle classification score 3 and above
4. Fitzpatrick skin type 2-5
5. Subject is capable of reading, understanding and following instructions of the procedure to be applied.
6. Subject is able and willing to comply with the treatment and follow-up schedule.

Exclusion Criteria

1. Subject has a pacemaker or internal defibrillator, implanted neurostimulators or any other internal electric device or patient who had an implant in the past.
2. Subject has metal or other implants in the treatment area (Not including dental fillings, implants and crowns).
3. Subject has current or history of cancer, especially skin cancer or premalignant moles or is undergoing any form of treatment for active cancer.
4. Subject has severe concurrent conditions such as epilepsy, lupus or cardiac disorders.
5. Subject has poorly controlled endocrine disorders such as diabetes.
6. Subject is female who is pregnant, lactating, or plans to become pregnant during the study period or had given birth less than 6 months ago.
7. Subject has an impaired immune system due to immunosuppressive diseases such as HIV or AIDS, or use of immunosuppressive medications.
8. Subject has a condition that could be negatively affected by heat, including any history of diseases stimulated by heat, such as recurrent Herpes Simplex (in the treatment area).
9. Subject has diminished or exaggerated perception of temperature changes.
10. Subject has significant concurrent skin conditions affecting areas to be treated such as sores, hemorrhages or risk of hemorrhages, septic conditions, psoriasis, eczema and rash as well as very dry and fragile skin.
11. Subject has history of collagen disorders, keloid formation and abnormal wound healing.
12. Subject has had previous invasive/ablative procedures in the areas to be treated within 3 months prior to initial treatment or plans on such treatment during the course of the study, or before complete healing has occurred.
13. Subject has had Botox injections in the treatment area within 6 months prior to initial treatment
14. Subject has had natural fillers within 9 months prior to initial treatment
15. Subject has synthetic fillers, injected chemical substance or gold/plastic threads in the treatment area.
16. Subject takes or has taken medications, herbal preparations, food supplements or vitamins that might cause fragile skin or impaired skin healing such as prolonged steroid regime, tetracyclines, or St. John's Wort for the last 3 months.
17. Subject has used oral isotretinoin (Accutane or Roaccutan) within 6 months prior to study enrollment or plans use during the course of the study.
18. Subject has history of bleeding coagulopathies or use of anticoagulants.
19. Use of non-steroidal anti inflammatory drugs (NSAIDS, e.g. ibuprofen containing agents) one week before and after each treatment session prior to treatment
20. Tattoo or permanent makeup in the treated area
21. Subject has burned, blistered, irritated, or sensitive skin due to excessive fresh tanning in areas to be treated or is unlikely to refrain from excessive tanning during the study.
22. Concurrent participation in any other study.
23. Subject has mental disorders that in the opinion of the Investigator would be interfere with ability to comply with the study requirements.
24. Subject is allergic to the topical anesthetic used in this study.

Minimum Eligible Age

35 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mira Barki, PhD

Role: STUDY_DIRECTOR

Pollogen Ltd.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tennessee Clinical Research Center

Nashville, Tennessee, United States

Site Status

Research Across America

Plano, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PC210117_F, rev. 01

Identifier Type: -

Identifier Source: org_study_id